CYP24A1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: A549 cell lysate, Primary antibody: P06881(CYP24A1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06881(CYP24A1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The CYP24A1 antibody targets the enzyme cytochrome P450 family 24 subfamily A member 1 (CYP24A1), a key regulator of vitamin D metabolism. This mitochondrial enzyme catalyzes the hydroxylation of active 1.25-dihydroxyvitamin D3 (calcitriol) and 25-hydroxyvitamin D3 into inactive metabolites, maintaining vitamin D homeostasis and preventing hypercalcemia. Dysregulation of CYP24A1 is linked to disorders like idiopathic infantile hypercalcemia (IIH) and chronic kidney disease, as well as cancers where overexpression may promote tumor progression by degrading anti-proliferative calcitriol.

CYP24A1 antibodies are widely used in research to study tissue-specific expression patterns, enzyme activity, and pathological mechanisms. They enable detection of CYP24A1 protein levels via techniques like immunohistochemistry, Western blotting, and ELISA. Commercially available antibodies are typically raised against specific epitopes of human CYP24A1. validated for specificity in various models. Clinically, these antibodies may aid in diagnosing genetic CYP24A1 deficiencies or assessing vitamin D status in metabolic diseases. Recent studies also explore their potential in cancer prognosis, as elevated CYP24A1 expression correlates with reduced calcitriol efficacy in malignancies. However, standardization of antibody validation remains critical to ensure accuracy across experimental and diagnostic applications.